Angiotensin Converting Enzyme Inhibitors

  • Theodore D. Mountokalakis
Chapter
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 217)

Abstract

The synthesis of the first orally active angiotensin converting enzyme (ACE) inhibitor in the 1977, heralded one of the major therapeutic advances of the last decades. Initially designed to be a pathophysiological meaningful tool for the treatment of severe malignant hypertension, ACE inhibitors are now widely accepted as first line approach to the treatment of mild to moderate essential hypertension and of congestive heart failure. In addition to the clinical importance of the results of clinical trials, studies aiming to elucidate the precise mode of action of these agents have led to the concept of tissue renin-angiotensin systems, and have clarified several aspects of the pathophysiology of hypertension and heart failure.

Keywords

Angiotensin Converting Enzyme Chronic Heart Failure Angiotensin Converting Enzyme Inhibitor Renal Artery Stenosis Joint National Committee 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Erdos EG. Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture. Hypertension 1990: 16: 368.CrossRefGoogle Scholar
  2. 2.
    Soubrier F, et al. Molecular biology of the angiotensin I converting enzyme: I. Biochemistry and structure of the gene. J Hypertens 1993, 11: 471.PubMedCrossRefGoogle Scholar
  3. 3.
    Bruneval P, et al. Angiotensin I converting enzyme in human intestine and kidney. Ultrastruc-ture and immunohistochemical localization. Histochemistry 1986, 85: 73.PubMedCrossRefGoogle Scholar
  4. 4.
    Arregin A, Iversen LL. Angiotensin-converting enzyme: presence of high activity in choroid plexus of mammalian brain. Eur J Pharmacol 1978: 52: 27.CrossRefGoogle Scholar
  5. 5.
    Costerousse O, et al. Angiotensin I-converting enzyme in human circulating mononuclear cells. Genetic polymorphism of expression in T-lymphocytes. Biochem J 1993, 290: 33.PubMedGoogle Scholar
  6. 6.
    Soubrier F, et al. Molecular biology of the angiotensin I converting enzyme: II. Structure-function. Gene polymorphism and clinical implications. J Hypertens 1993, 11: 599.PubMedCrossRefGoogle Scholar
  7. 7.
    Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 1977, 196: 441.PubMedCrossRefGoogle Scholar
  8. 8.
    Wei L, et al. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem 1992, 267: 13398.PubMedGoogle Scholar
  9. 9.
    Samani NJ. New developments in renin and hypertension. Tissue generation of angiotensin I and II changes the picture. Br Med J 1991, 302: 981.CrossRefGoogle Scholar
  10. 10.
    Schunkert H, et al. Riegger GA.J. Association between a deletion polymorphism of the angiotesin-converting enzyme gene and left ventricular hypertrophy. N Engl J Med 1994, 330: 1637.CrossRefGoogle Scholar
  11. 11.
    Carbonell LF, et al. Effect of a kinin antagonists on the acute antihypertensive activity of enalapril in severe hypertension. Hypertension 1988, 11: 239.PubMedCrossRefGoogle Scholar
  12. 12.
    Spertini F, et al. Opposing effects of chronic angiotensin-converting enzyme blockade by captopril on the responses to exogenous angiotensin II and vasopressin vs norepinephrine in rats. Circ Res 1981, 48: 621.CrossRefGoogle Scholar
  13. 13.
    Oparil S, et al. Antihypertensive effect of enalapril in essential hypertension: role of prostacyclin. Am J Med Sci 1987, 294: 395.PubMedCrossRefGoogle Scholar
  14. 14.
    McInnes GT, Stergiou GS. Clinical pharmacology of ACE inhibitors. In: Cleland JGF (ed.) The clinician’s guide to ACE inhibition. Edinburgh, London, Churchill Livingstone 1993: 23.Google Scholar
  15. 15.
    Yeo WW, Ramsey LE, Jackson PR. ACE inhibitors and hypertension. In: Cleland JGF (ed.) The clinician’s guide to ACE inhibition. Edinburgh, London, Churchill Livingstone 1993: 37.Google Scholar
  16. 16.
    Sambhi MP, et al. Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension-do we need more clinical trials? West J Med 1993, 158: 286.PubMedGoogle Scholar
  17. 17.
    Weber MA, Laragh JH. Hypertension: Steps forward and steps backward. Arch Intern Med 1993, 153: 149.PubMedCrossRefGoogle Scholar
  18. 18.
    The Joint National Committee on Detection, Evaluation, and Treatment og High Blood Pressure. The fifth report on the Joint National Committee on Detection, Evaluation, and Treatment og High Blood Pressure. Arch Intern Med 1993, 153: 154.CrossRefGoogle Scholar
  19. 19.
    Brunner HR, Waeber B, Nussberger J. Angiotensin converting enzyme inhibition and the normal kidney. Kidney Int 1987, 31 (Suppl 20): 5104.Google Scholar
  20. 20.
    Mogensen CE. Angiotensin converting enzyme inhibitors and diabetic nephropathy. Their effects on proteinuria may be independent of their effects on blood pressure. Br Med J 1992, 304: 327.CrossRefGoogle Scholar
  21. 21.
    Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989, 321: 868.PubMedCrossRefGoogle Scholar
  22. 22.
    Dzau VJ, Gibbons G. Cell biology of vascular hypertrophy in hypertension. Am J Cardiol 1988, 62: 30G.PubMedCrossRefGoogle Scholar
  23. 23.
    Anderson WP, Woods RL. Intrarenal effects of angiotension II in renal artery stenosis. Kidney Int 1987, 31 (Suppl 20): 5157.Google Scholar
  24. 24.
    Yeo WW, Foster G, Ramsay LE. Prevalence of cough in patients taking enalapril: controlled study versus nifedipine. Quart J Med 1991, 239: 763.Google Scholar
  25. 25.
    Hedner T, et al. Angioedema in relation to angiotensin converting enzyme inhibitors. Br Med J 1992, 304: 941.CrossRefGoogle Scholar
  26. 26.
    Packer M. Treatment of chronic heart failure. Lancet 1992, 340: 92.PubMedCrossRefGoogle Scholar
  27. 27.
    Cleeland JGF. The haemodynamic effects of ACE inhibitors. In: Cleland JGF (ed.) The clinician’s guide to ACE inhibition. Edingurgh, London, Churchill Livingstone 1993: 76.Google Scholar
  28. 28.
    Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987, 316: 1429.CrossRefGoogle Scholar
  29. 29.
    Solv D Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325: 293.CrossRefGoogle Scholar
  30. 30.
    Poole-Wilson PA, Lindsay D. Advances in the treatment of chronic heart failure. Br Med J 1992, 304: 1069.CrossRefGoogle Scholar
  31. 31.
    Packer M, et al. for the RADIANCE study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993, 329: 1.PubMedCrossRefGoogle Scholar
  32. 32.
    Hood WB, Youngblood M, Ghali JK, et al for the SOLVD investigators. Initial blood pressure response to enalapril in hospitalized patients (studies of left ventricular dysfunction [SOLVD]). Am J Cardiol 1991, 68: 1465.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Theodore D. Mountokalakis

There are no affiliations available

Personalised recommendations